Table 4.
Risk factors for progression-free survival and post-progression survival.
| Characteristics | Univariate Cox | Multivariate Cox | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Progression-free survival | ||||
| Cohort: PLAGH vs. PUMCH | 1.16 (0.66-2.02) | 0.608 | ||
| Group: ICI+Others vs. ICI+Lenva | 1.35 (0.77-2.37) | 0.297 | ||
| Age: ≥ 65 vs. < 65 | 0.83 (0.42-1.64) | 0.585 | ||
| Sex: Male vs. Female | 0.73 (0.37-1.46) | 0.375 | ||
| HBV infection: Yes vs. No | 1.23 (0.61-2.51) | 0.563 | ||
| HCV infection: Yes vs. No | 0.69 (0.1-5.05) | 0.719 | ||
| Alcohol consumption: Yes vs. No | 1.02 (0.57-1.8) | 0.956 | ||
| ECOG: 1-2 vs. 0 | 1.95 (1.13-3.37) | 0.017 | 1.66 (0.94-2.94) | 0.079 |
| Child–Pugh: B vs. A | 1.85 (1.08-3.18) | 0.025 | 1.65 (0.94-2.91) | 0.081 |
| AFP (ng/ml): ≥ 400 vs. < 400 | 1.74 (1.03-2.94) | 0.037 | 1.75 (1.03-2.97) | 0.037 |
| Tumor number: ≥ 2 vs. 1 | 1.54 (0.61-3.85) | 0.359 | ||
| Macrovascular invasion: Yes vs. No | 1.38 (0.83-2.29) | 0.216 | ||
| Extrahepatic Metastasis: Yes vs. No | 1.14 (0.67-1.92) | 0.635 | ||
| BCLC staging: C vs. B | 1.3 (0.52-3.26) | 0.576 | ||
| Tumor size (cm): ≥ 5 vs. < 5 | 1.2 (0.69-2.08) | 0.513 | ||
| Previous systemic treatment: Yes vs. No | 0.92 (0.53-1.57) | 0.753 | ||
| Previous locoregional treatment: Yes vs. No | 2.08 (0.83-5.2) | 0.118 | ||
| Concomitant locoregional treatment: Yes vs. No | 0.84 (0.47-1.49) | 0.553 | ||
| Post-progression survival | ||||
| Cohort: PLAGH vs. PUMCH | 1.25 (0.67-2.32) | 0.487 | ||
| Group: ICI+Others vs. ICI+Lenva | 0.92 (0.49-1.7) | 0.785 | ||
| Age: ≥ 65 vs. < 65 | 0.86 (0.42-1.76) | 0.671 | ||
| Sex: Male vs. Female | 1.54 (0.61-3.87) | 0.362 | ||
| HBV infection: Yes vs. No | 0.95 (0.5-1.82) | 0.888 | ||
| HCV infection: Yes vs. No | 2.17 (0.67-7.05) | 0.197 | ||
| Alcohol consumption: Yes vs. No | 0.98 (0.51-1.87) | 0.949 | ||
| ECOG: 1-2 vs. 0 | 2.34 (1.28-4.27) | 0.006 | 1.69 (0.89-3.22) | 0.11 |
| Child–Pugh: B vs. A | 2.1 (1.17-3.75) | 0.012 | 1.96 (1.05-3.65) | 0.034 |
| AFP (ng/ml): ≥ 400 vs. < 400 | 2.16 (1.24-3.76) | 0.007 | 2.37 (1.35-4.17) | 0.003 |
| Tumor number: ≥ 2 vs. 1 | 1.9 (0.59-6.13) | 0.28 | ||
| Macrovascular invasion: Yes vs. No | 1.28 (0.74-2.22) | 0.38 | ||
| Extrahepatic Metastasis: Yes vs. No | 1.51 (0.87-2.62) | 0.147 | ||
| BCLC staging: C vs. B | 1.94 (0.7-5.4) | 0.203 | ||
| Tumor size (cm): ≥ 5 vs. < 5 | 1.86 (0.99-3.51) | 0.054 | ||
| Previous systemic treatment: Yes vs. No | 1.06 (0.59-1.91) | 0.833 | ||
| Previous locoregional treatment: Yes vs. No | 1.46 (0.62-3.44) | 0.382 | ||
| Concomitant locoregional treatment: Yes vs. No | 0.35 (0.16-0.75) | 0.007 | 0.33 (0.15-0.72) | 0.005 |
PUMCH, Peking Union Medical College Hospital; PLAGH, Chinese Peoples’ Liberation Army General Hospital; HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, no HBV or HCV infection; AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer.